Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
To determine the efficacy and safety of low, nonescalating dose tissue plasminogen activator (rt-PA) in restoring the patency of occluded central venous access devices (CVCs) in children with cancer who weigh less than 30 kg. A single-center review of the use of rt-PA (0.5 mg indwelling for 30 minutes in the CVC) was conducted in 42 cancer patients with large bore central venous access devices implanted over a 2-year period. All patients weighed less than 30 kg. None had been previously treated with a thrombolytic agent. The efficacy for restoring function to CVCs was measured and correlated with patient age, weight and CVC lumen size. Propensity to rethrombose following an initial occlusion and treatment was also determined. Of 235 doses of rt-PA administered in a 2-year period, 55 doses administered to 42 patients met the eligibility criteria as outlined. Twenty-nine patients (69%) had function restored with a single dose; 8 patients (19%) required 2 doses, and 5 patients (12%) failed 2 doses; for an overall success rate of 88%. No significant adverse events occurred. Of the 37 cleared CVCs, 14 (38%) reoccluded within 1 month. A higher proportion of patients initially treated with one rt-PA (71%) experienced another CVC dysfunction within 1 month, compared with 29% CVC dysfunction in those requiring >1 dose. This article describes the use of rt-PA (0.5 mg, without dose escalation) to lyse CVC-associated thrombi specifically in small children with cancer, a patient population in which it is particularly desirable to minimize the degree of fibrinolysis. One dose of 0.5 mg rt-PA, with an additional dose if necessary, is as safe and effective as previously reported escalating dose regimens for CVC clot lysis. There is no statistically significant correlation of treatment failure with patient age, weight, or catheter lumen size, and no significant propensity for rapid rethrombosis following a single dysfunction and treatment. Patients initially treated with a single dose of rt-PA appear to have more subsequent dysfunctions in the month after treatment, an observation that warrants further study.